Lars Torup

3.3k total citations
23 papers, 1.1k citations indexed

About

Lars Torup is a scholar working on Cellular and Molecular Neuroscience, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Lars Torup has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cellular and Molecular Neuroscience, 7 papers in Pathology and Forensic Medicine and 6 papers in Epidemiology. Recurrent topics in Lars Torup's work include Alcohol Consumption and Health Effects (7 papers), Substance Abuse Treatment and Outcomes (5 papers) and Neurotransmitter Receptor Influence on Behavior (5 papers). Lars Torup is often cited by papers focused on Alcohol Consumption and Health Effects (7 papers), Substance Abuse Treatment and Outcomes (5 papers) and Neurotransmitter Receptor Influence on Behavior (5 papers). Lars Torup collaborates with scholars based in Denmark, Germany and Netherlands. Lars Torup's co-authors include Antoni Gual, Karl Mann, Wim van den Brink, Anna Bladström, Yuan He, Marcel Leist, Per Soelberg Sørensen, Jens Gerwien, Pietro Ghezzi and Johan van Beek and has published in prestigious journals such as Journal of Biological Chemistry, Biological Psychiatry and Brain Research.

In The Last Decade

Lars Torup

21 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Torup Denmark 13 472 338 331 216 212 23 1.1k
Jeanna Tsenter Israel 15 347 0.7× 48 0.1× 195 0.6× 516 2.4× 134 0.6× 26 1.3k
Claudia Bartels Germany 12 99 0.2× 87 0.3× 127 0.4× 216 1.0× 213 1.0× 16 914
Wooyoung Jang South Korea 16 134 0.3× 97 0.3× 131 0.4× 319 1.5× 45 0.2× 35 833
Ilaria Simonelli Italy 22 97 0.2× 268 0.8× 74 0.2× 163 0.8× 70 0.3× 52 1.4k
Andrew Slivka United States 21 691 1.5× 78 0.2× 177 0.5× 592 2.7× 33 0.2× 48 1.6k
Mary S. Lange United States 16 94 0.2× 129 0.4× 165 0.5× 198 0.9× 58 0.3× 22 1.2k
Peter Turčáni Slovakia 18 278 0.6× 213 0.6× 72 0.2× 324 1.5× 17 0.1× 100 1.3k
Karen J. Kluin United States 27 93 0.2× 82 0.2× 720 2.2× 759 3.5× 150 0.7× 45 2.3k
Florence Wahl France 16 218 0.5× 64 0.2× 393 1.2× 451 2.1× 24 0.1× 20 1.0k
Akiro Terashi Japan 19 319 0.7× 51 0.2× 100 0.3× 150 0.7× 40 0.2× 65 1.4k

Countries citing papers authored by Lars Torup

Since Specialization
Citations

This map shows the geographic impact of Lars Torup's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Torup with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Torup more than expected).

Fields of papers citing papers by Lars Torup

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Torup. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Torup. The network helps show where Lars Torup may publish in the future.

Co-authorship network of co-authors of Lars Torup

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Torup. A scholar is included among the top collaborators of Lars Torup based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Torup. Lars Torup is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mann, Karl, Lars Torup, Per Soelberg Sørensen, et al.. (2016). Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. European Neuropsychopharmacology. 26(12). 1941–1949. 61 indexed citations
2.
Aubin, Henri‐Jean, Jens Reimer, David Nutt, et al.. (2015). Clinical Relevance of As-Needed Treatment with Nalmefene in Alcohol-Dependent Patients. European Addiction Research. 21(3). 160–168. 27 indexed citations
3.
Aubin, Henri‐Jean, Jens Reimer, David Nutt, et al.. (2014). EPA-0255 – Clinical relevance of as-needed treatment with nalmefene in alcohol dependent patients. European Psychiatry. 29. 1–1.
4.
Brink, Wim van den, et al.. (2014). Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. Journal of Psychopharmacology. 28(8). 733–744. 78 indexed citations
5.
6.
Gual, Antoni, Yuan He, Lars Torup, Wim van den Brink, & Karl Mann. (2013). A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. European Neuropsychopharmacology. 23(11). 1432–1442. 166 indexed citations
7.
Brink, Wim van den, Henri‐Jean Aubin, Anna Bladström, et al.. (2013). 1107 – Esense 1 - Randomised Controlled 6-month Study Of As-needed Nalmefene: Subgroup Analysis Of Alcohol Dependent Patients With High Drinking Risk Level. European Psychiatry. 28(S1). 1 indexed citations
8.
9.
Mann, Karl, Anna Bladström, Lars Torup, Antoni Gual, & Wim van den Brink. (2012). Extending the Treatment Options in Alcohol Dependence: A Randomized Controlled Study of As-Needed Nalmefene. Biological Psychiatry. 73(8). 706–713. 209 indexed citations
10.
Mann, Karl, Anna Bladström, Lars Torup, Antoni Gual, & Wim van den Brink. (2012). P-59 - Shifting the paradigm: reduction of alcohol consumption in alcohol dependent patients - a randomised, double-blind, placebo-controlled study of nalmefene, as-needed use. European Psychiatry. 27. 1–1. 2 indexed citations
11.
Sams, Anette, et al.. (2010). Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 20(17). 5241–5244. 10 indexed citations
12.
Wang, Lei, Zheng Gang Zhang, Sara R Gregg, et al.. (2007). The Sonic Hedgehog Pathway Mediates Carbamylated Erythropoietin-enhanced Proliferation and Differentiation of Adult Neural Progenitor Cells. Journal of Biological Chemistry. 282(44). 32462–32470. 91 indexed citations
13.
King, Von R., et al.. (2007). Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. European Journal of Neuroscience. 26(1). 90–100. 73 indexed citations
14.
Mennini, Tiziana, Massimiliano De Paola, Paolo Bigini, et al.. (2006). Nonhematopoietic Erythropoietin Derivatives Prevent Motoneuron Degeneration In Vitro and In Vivo. Molecular Medicine. 12(7-8). 153–160. 70 indexed citations
15.
Villa, Pia, Johan van Beek, Anna Kirstine Larsen, et al.. (2006). Reduced Functional Deficits, Neuroinflammation, and Secondary Tissue Damage after Treatment of Stroke by Nonerythropoietic Erythropoietin Derivatives. Journal of Cerebral Blood Flow & Metabolism. 27(3). 552–563. 130 indexed citations
16.
Torup, Lars, et al.. (2003). Neuroprotective effect of the neurotensin analogue JMV-449 in a mouse model of permanent middle cerebral ischaemia. Neuroscience Letters. 351(3). 173–176. 18 indexed citations
17.
18.
19.
Torup, Lars & Nils Henrik Diemer. (2000). Is the 5-HT2C Receptor a Therapeutic Target in Cerebral Ischaemia?. Pharmacology & Toxicology. 87(2). 74–78. 2 indexed citations
20.
Torup, Lars, Erling T. Mellerup, & Nils Henrik Diemer. (1999). Density of serotonin receptors in rat brain following global cerebral ischemia: An autoradiographic study. Neuroscience Research Communications. 24(1). 33–40. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeanna Tsenter Breakdown of academic impact, for papers by Claudia Bartels Breakdown of academic impact, for papers by Wooyoung Jang Breakdown of academic impact, for papers by Ilaria Simonelli Breakdown of academic impact, for papers by Andrew Slivka Breakdown of academic impact, for papers by Mary S. Lange Breakdown of academic impact, for papers by Peter Turčáni Breakdown of academic impact, for papers by Karen J. Kluin Breakdown of academic impact, for papers by Florence Wahl Breakdown of academic impact, for papers by Akiro Terashi
Rankless by CCL
2026